Impact of bevacizumab in combination with erlotinib onEGFR-mutated non-small cell lung cancer xenograft models with T790M mutation orMETamplification

MLA

Junko Fukumura, et al. “Impact of Bevacizumab in Combination with Erlotinib OnEGFR-Mutated Non-Small Cell Lung Cancer Xenograft Models with T790M Mutation OrMETamplification.” International Journal of Cancer, vol. 138, Oct. 2015, pp. 1024–32. EBSCOhost, https://doi.org/10.1002/ijc.29848.

APA

Junko Fukumura, Naoki Harada, Koh Furugaki, Kaname Yamamoto, Mitsue Kurasawa, Keigo Yorozu, Mieko Yanagisawa, Kenichi Suda, Yoichiro Moriya, Toshiki Iwai, Tetsuya Mitsudomi, & Hiroshi Mizuuchi. (2015). Impact of bevacizumab in combination with erlotinib onEGFR-mutated non-small cell lung cancer xenograft models with T790M mutation orMETamplification. International Journal of Cancer, 138, 1024–1032. https://doi.org/10.1002/ijc.29848

Chicago

Junko Fukumura, Naoki Harada, Koh Furugaki, Kaname Yamamoto, Mitsue Kurasawa, Keigo Yorozu, Mieko Yanagisawa, et al. 2015. “Impact of Bevacizumab in Combination with Erlotinib OnEGFR-Mutated Non-Small Cell Lung Cancer Xenograft Models with T790M Mutation OrMETamplification.” International Journal of Cancer 138 (October): 1024–32. doi:10.1002/ijc.29848.